Indication
MF
2 clinical trials
3 products
1 drug
Product
JAB-8263Clinical trial
A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant TumorsStatus: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibStatus: Recruiting, Estimated PCD: 2026-12-31
Drug
NavtemadlinProduct
NavtemadlinProduct
Ruxolitinib